US and UK Reach No-Tariff Arrangement on Prescription Drugs.
The UK and US have secured a significant bilateral deal that will ensure no import taxes on UK pharmaceutical products entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these vital exports will stay at zero for a duration of three years.
This deal is in response to recent threats to dramatically increase import taxes on branded drug products, with increases mentioned reaching 100%.
"This deal with the UK bolsters the global environment for new treatments and introduces much-needed balance to transatlantic drug exports," a statement declared.
Commercial Significance
Medicines constitute one of the the United Kingdom's biggest exports to the US, which is clearly the biggest market for leading UK drugmakers.
Statistics show that in the year prior to the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This figure made up 17.4% of British export trade in that timeframe.
"This deal safeguards employment, increases investment and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The deal includes several notable changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total health service expenditure on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, rebates exceeded twenty percent.
Recent Tensions
The deal comes amid a long-running row between the sector and the UK government over medicine costs and approval rates.
These tensions were exacerbated by arguments that American patients were charged a premium for the same drugs than patients in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its resources over the past decade.
